7467-42-7

Usage

Uses

Used in Pharmaceutical Industry:
4-aminobenzamidopyridine is used as a chemical intermediate for the synthesis of various drugs and pharmaceuticals, specifically in the production of anti-inflammatory and analgesic medications. Its structural components facilitate the development of compounds that can effectively address inflammation and pain.
Used in Cancer Treatment:
4-aminobenzamidopyridine is studied for its potential use in photodynamic therapy, a treatment modality that employs light and a photosensitizing chemical to target and destroy cancer cells. Its photochemical properties make it a candidate for this targeted approach to cancer treatment.
Used in Anti-Tumor Research:
4-aminobenzamidopyridine has been researched for its potential anti-tumor properties, with studies exploring its ability to inhibit the growth of cancer cells. This application underscores its potential as a therapeutic agent in oncology, offering a new avenue for the development of cancer treatments.

InChI:InChI=1/C12H11N3O.2ClH/c13-10-6-4-9(5-7-10)12(16)15-11-3-1-2-8-14-11;;/h1-8H,13H2,(H,14,15,16);2*1H

Upstream product

• 504-29-0 2-aminopyridine 
• 66493-39-8 4-(N-tert-butoxycarbonyl)aminobenzoic acid 
• 62-23-7 4-nitro-benzoic acid 
• 7498-40-0 4-nitro-N-pyridine-2-yl-benzamide 

Downstream Products

• 1261035-36-2 N-(pyridine-2-yl)-4-dodecanamido-benzamide 
• 1261035-37-3 N-(pyridin-2-yl)-4-stearamidobenzamide 
• 1372892-86-8 4-((3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino)-N-(pyridin-2-yl)benzamide 

Relevant academic research and scientific papers

ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION

The present invention relates to a compound of formula (I) wherein X1 represents an alkenylene group, a -NH-CO- group, a -CO-NH- group, Y1 represents an aryl group selected from a pyridyl group, a pyrazinyl group or a pyrimidinyl group, X2 represents a -O- group, a-CO-NH- group, a -NH-CO-NH- group, a -OCH2- group, a -NH-CO- group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms or a -SO2-NH- group, and Y2 represents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or a -CR1R2R3 group or alternatively X2-Y2 represents a group -CONRcRd, wherein Rc and Rd form, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification. The present invention further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.

S-triazine compounds as well as preparation method and application thereof

The invention discloses s-triazine compounds and pharmaceutically acceptable salts thereof; experiments prove that the compounds can be used for treating or preventing diseases related to protein kinase activity, such as leukemia and lymphoma, by inhibiti

Amido pyrimidine compound

The invention provides an amido pyrimidine compound with a novel structure as shown in a formula (I) and a preparation method and application of the amido pyrimidine compound. The amido pyrimidine compound is a compound shown as the formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof and the like. The amido pyrimidine compound provided bythe invention has a relatively good proliferation inhibition effect on various cancer cells; according to the present invention, the compound has characteristics of low tumor cell inhibition concentration, significantly-improved compound activity, good tumor cell selectivity and good solubility, and is expected to be a specific drug for treatment of malignant tumor cell abnormal proliferation diseases caused by EGFR mutation.

AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES

The invention relates to new compounds with low cytotoxicity for blocking the ubiquitination- proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders, autoimmune disorders and metabolic disorders.

PARA AMINO BENZOIC ACID BASED NANOTUBES

The invention relates to nanotubes and processes for making them and intermediates of a drug moiety or its derivative/s as a structural moiety with side chain/s capable of promoting self aggregation. The side chain/s are mono or a multiple of alkyl chain/

PARA AMINO BENZOIC ACID BASED NANOTUBES

The invention comprises nanotubes and a process for making same and its intermediates comprising a drug moiety or its derivative/s as a structural moiety that further has side chain/s capable of promoting self aggregation and/or performing a functionality